Morepen Adds ‘Blockbusters’ To API Portfolio
The Indian Firm Is Eyeing A Move Up The Value Chain
Executive Summary
India’s Morepen Laboratories has added two “blockbuster drugs” and one niche product to its API portfolio for sale in its domestic and global markets as it looks to move up the value chain following approval for its in-house R&D center.